94 related articles for article (PubMed ID: 8489766)
21. Evaluating current methods for determination of the susceptibility of mycobacteria to pyrazinamide, conventional, radiometric Bactec and two methods of pyrazinamidase testing.
Cutler RR; Wilson P; Villarroel J; Clarke FV
Lett Appl Microbiol; 1997 Feb; 24(2):127-32. PubMed ID: 9081306
[TBL] [Abstract][Full Text] [Related]
22. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Masood N; Nadeem T; Khan AS; Afzal MT
BMC Infect Dis; 2019 Feb; 19(1):116. PubMed ID: 30728001
[TBL] [Abstract][Full Text] [Related]
23. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
Bwalya P; Yamaguchi T; Mulundu G; Nakajima C; Mbulo G; Solo ES; Fukushima Y; Kasakwa K; Suzuki Y
Tuberculosis (Edinb); 2018 Mar; 109():117-122. PubMed ID: 29559115
[TBL] [Abstract][Full Text] [Related]
24. Pyrazinamide Susceptibility and
Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
[TBL] [Abstract][Full Text] [Related]
25. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains.
Dormandy J; Somoskovi A; Kreiswirth BN; Driscoll JR; Ashkin D; Salfinger M
Chest; 2007 Feb; 131(2):497-501. PubMed ID: 17296653
[TBL] [Abstract][Full Text] [Related]
26. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.
Salfinger M; Heifets LB
Antimicrob Agents Chemother; 1988 Jul; 32(7):1002-4. PubMed ID: 3142340
[TBL] [Abstract][Full Text] [Related]
27. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Permar S; Sun Z
J Med Microbiol; 2002 Jan; 51(1):42-49. PubMed ID: 11800471
[TBL] [Abstract][Full Text] [Related]
28. Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 mycobacterium tuberculosis clinical isolates.
Mestdagh M; Realini L; Fonteyne PA; Rossau R; Jannes G; Mijs W; DE Smet KA; Portaels F; Van den Eeckhout E
Microb Drug Resist; 2000; 6(4):283-7. PubMed ID: 11272256
[TBL] [Abstract][Full Text] [Related]
29. Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Butler WR; Kilburn JO
J Clin Microbiol; 1982 Dec; 16(6):1106-9. PubMed ID: 6819309
[TBL] [Abstract][Full Text] [Related]
30. Pyrazinamidase activity of Mycobacterium tuberculosis--a test of sensitivity to pyrazinamide.
Trivedi SS; Desai SG
Tubercle; 1987 Sep; 68(3):221-4. PubMed ID: 3129848
[TBL] [Abstract][Full Text] [Related]
31. Revisiting problems and solutions to decrease Mycobacterium tuberculosis pyrazinamide false resistance when using the Bactec MGIT 960 system.
Mustazzolu A; Piersimoni C; Iacobino A; Giannoni F; Chirullo B; Fattorini L
Ann Ist Super Sanita; 2019; 55(1):51-54. PubMed ID: 30968836
[TBL] [Abstract][Full Text] [Related]
32. Pyrazinamide is not active in vitro against Mycobacterium avium complex.
Heifets LB; Iseman MD; Crowle AJ; Lindholm-Levy PJ
Am Rev Respir Dis; 1986 Dec; 134(6):1287-8. PubMed ID: 3789528
[TBL] [Abstract][Full Text] [Related]
33. [Investigation of pyrazinamide resistance in multidrug-resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey].
Senol G; Coşkun M; Gündüz AT; Biçmen C; Gayaf M; Ozsöz A
Mikrobiyol Bul; 2008 Oct; 42(4):591-7. PubMed ID: 19149080
[TBL] [Abstract][Full Text] [Related]
34. Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay.
Syre H; Øvreås K; Grewal HM
J Antimicrob Chemother; 2010 Apr; 65(4):704-12. PubMed ID: 20118493
[TBL] [Abstract][Full Text] [Related]
35. Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960.
Maslov DA; Zaĭchikova MV; Chernousova LN; Shur KV; Bekker OB; Smirnova TG; Larionova EE; Andreevskaya SN; Zhang Y; Danilenko VN
Tuberculosis (Edinb); 2015 Sep; 95(5):608-12. PubMed ID: 26071666
[TBL] [Abstract][Full Text] [Related]
36. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing.
Shenai S; Rodrigues C; Sadani M; Sukhadia N; Mehta A
Indian J Tuberc; 2009 Apr; 56(2):82-90. PubMed ID: 19810590
[TBL] [Abstract][Full Text] [Related]
37. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
38. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.
Scorpio A; Zhang Y
Nat Med; 1996 Jun; 2(6):662-7. PubMed ID: 8640557
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates.
Huy NQ; Lucie C; Hoa TTT; Hung NV; Lan NTN; Son NT; Nhung NV; Anh DD; Anne-Laure B; Van Anh NT
Emerg Microbes Infect; 2017 Oct; 6(10):e86. PubMed ID: 29018250
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
Salfinger M; Kafader FM
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jul; 265(3-4):404-7. PubMed ID: 3118600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
